TW200700082A - Therapy of prostate cancer with ctla4 antibodies and hormonal therapy - Google Patents
Therapy of prostate cancer with ctla4 antibodies and hormonal therapyInfo
- Publication number
- TW200700082A TW200700082A TW095107225A TW95107225A TW200700082A TW 200700082 A TW200700082 A TW 200700082A TW 095107225 A TW095107225 A TW 095107225A TW 95107225 A TW95107225 A TW 95107225A TW 200700082 A TW200700082 A TW 200700082A
- Authority
- TW
- Taiwan
- Prior art keywords
- therapy
- prostate cancer
- hormonal
- antibody
- ctla4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66436405P | 2005-03-23 | 2005-03-23 | |
US71170705P | 2005-08-26 | 2005-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200700082A true TW200700082A (en) | 2007-01-01 |
Family
ID=36666381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095107225A TW200700082A (en) | 2005-03-23 | 2006-03-03 | Therapy of prostate cancer with ctla4 antibodies and hormonal therapy |
Country Status (13)
Country | Link |
---|---|
US (1) | US20080279865A1 (zh) |
EP (1) | EP1868644A1 (zh) |
JP (1) | JP2006265244A (zh) |
KR (1) | KR20070108259A (zh) |
AR (1) | AR053690A1 (zh) |
AU (1) | AU2006227879A1 (zh) |
BR (1) | BRPI0609427A2 (zh) |
CA (1) | CA2602956A1 (zh) |
IL (1) | IL185463A0 (zh) |
MX (1) | MX2007010603A (zh) |
RU (1) | RU2007134867A (zh) |
TW (1) | TW200700082A (zh) |
WO (1) | WO2006101691A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087577A2 (en) * | 2008-01-07 | 2009-07-16 | Patrys Limited | Barb4 target, antibody designated barb4, barb4 related antibodies, and methods of making and using same |
US8449886B2 (en) | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
EP3632459A1 (en) | 2008-07-17 | 2020-04-08 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
CN107746852B (zh) | 2012-05-04 | 2021-10-08 | 辉瑞公司 | 前列腺相关抗原及基于疫苗的免疫治疗疗法 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
EA030128B1 (ru) | 2012-09-26 | 2018-06-29 | Арагон Фармасьютикалз, Инк. | Способ лечения неметастатического кастрационно-резистентного рака простаты |
JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
HUE044730T2 (hu) | 2013-09-20 | 2019-11-28 | Bristol Myers Squibb Co | Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére |
WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
EP3331917A1 (en) | 2015-08-04 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
JP2020513819A (ja) * | 2017-03-15 | 2020-05-21 | スージョウ ギャラクシー バイオファーマ カンパニー リミテッド | Ctla4抗体、医薬組成物およびその使用 |
BR112019020610A2 (pt) | 2017-05-30 | 2020-04-22 | Bristol-Myers Squibb Company | tratamento de tumores positivos para o lag-3 |
CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
SG11202011521RA (en) * | 2018-06-01 | 2020-12-30 | Univ Yale | Compositions and methods for treating steroid hormone-related diseases or disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051227A (en) * | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) * | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
JP2001523958A (ja) * | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
KR100856446B1 (ko) * | 1998-12-23 | 2008-09-04 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
US7109003B2 (en) * | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
ES2282133T3 (es) * | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
JP2005529873A (ja) * | 2002-04-12 | 2005-10-06 | メダレックス インコーポレイテッド | Ctla−4抗体を使用した治療の方法 |
JP2006500931A (ja) * | 2002-09-30 | 2006-01-12 | ファイザー・プロダクツ・インク | 高レベルのヒト配列抗体を産生するハイブリドーマ |
KR100845354B1 (ko) * | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항-ctla-4 항체의 용도 |
-
2006
- 2006-03-03 JP JP2006057537A patent/JP2006265244A/ja not_active Withdrawn
- 2006-03-03 TW TW095107225A patent/TW200700082A/zh unknown
- 2006-03-03 US US11/817,390 patent/US20080279865A1/en not_active Abandoned
- 2006-03-03 CA CA002602956A patent/CA2602956A1/en not_active Abandoned
- 2006-03-03 RU RU2007134867/14A patent/RU2007134867A/ru unknown
- 2006-03-03 AU AU2006227879A patent/AU2006227879A1/en not_active Abandoned
- 2006-03-03 BR BRPI0609427-9A patent/BRPI0609427A2/pt not_active IP Right Cessation
- 2006-03-03 KR KR1020077021945A patent/KR20070108259A/ko not_active Application Discontinuation
- 2006-03-03 WO PCT/US2006/007650 patent/WO2006101691A1/en active Application Filing
- 2006-03-03 MX MX2007010603A patent/MX2007010603A/es unknown
- 2006-03-03 AR ARP060100821A patent/AR053690A1/es unknown
- 2006-03-03 EP EP06736896A patent/EP1868644A1/en not_active Withdrawn
-
2007
- 2007-08-22 IL IL185463A patent/IL185463A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006101691A1 (en) | 2006-09-28 |
AR053690A1 (es) | 2007-05-16 |
CA2602956A1 (en) | 2006-09-28 |
KR20070108259A (ko) | 2007-11-08 |
BRPI0609427A2 (pt) | 2010-04-06 |
EP1868644A1 (en) | 2007-12-26 |
RU2007134867A (ru) | 2009-04-27 |
MX2007010603A (es) | 2007-10-18 |
IL185463A0 (en) | 2008-01-06 |
US20080279865A1 (en) | 2008-11-13 |
JP2006265244A (ja) | 2006-10-05 |
AU2006227879A1 (en) | 2006-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200700082A (en) | Therapy of prostate cancer with ctla4 antibodies and hormonal therapy | |
WO2009005809A3 (en) | Compositions and methods for treating and diagnosing cancer | |
WO2002080754A3 (en) | Methods for using annexin for detecting cell death in vivo and treating associated conditions | |
WO2002069896A3 (en) | Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation | |
WO2001072962A3 (en) | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
IL244803A0 (en) | Human anti-beta7 antibodies and their use | |
WO2004014292A3 (en) | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF | |
TW200621804A (en) | Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer | |
EA200700225A1 (ru) | Аналоги тетрапептида | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
WO2004064727A3 (en) | Method of cancer treatment using hdac inhibitors | |
WO2003013430A3 (en) | Benzoquinone ansamycins | |
DK1648905T3 (da) | Inhibitorer for thienopyridin- og furopyridinkinase | |
EP1755659A4 (en) | USE OF ANTI-ALPHA5BETA1 ANTIBODIES TO INHIBIT CANCER CELL PROLIFERATION | |
NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
WO2006071952A3 (en) | Compositions and methods for improving kidney function | |
AU2000233235A1 (en) | Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase | |
MX2009001440A (es) | Composiciones y metodos que utilizan anticuerpos anti-cs1 para tratar mieloma multiple. | |
WO2005051307A3 (en) | Epha2 agonistic monoclonal antibodies and methods of use thereof | |
EP1708751A4 (en) | METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS | |
ATE510553T1 (de) | Beta-2-glycoprotein 1 als angiogenesehemmer | |
BR0314369A (pt) | Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado | |
WO2006015191A3 (en) | Multicyclic lonidamine analogs | |
WO2004110245A3 (en) | Combination therapy for cancer treatment | |
WO2003013431A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer |